Carlsmed publicly filed a registration statement with the SEC relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Carlsmed has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol CARL.
BofA Securities, Goldman Sachs and Piper Sandler are acting as joint lead book-running managers and representatives of the underwriters for the proposed offering. Truist Securities and BTIG are acting as joint book-runners for the proposed offering.
The proposed offering will be made only by means of a prospectus.
The aprevo Technology Platform consists of artificial intelligence-enabled software solutions and interbody implants that are custom-designed for each patient’s pathology and vertebral bone topography, as well as single-use surgical instruments. The aprevo Technology Platform was designed to address the limitations of traditional spine fusion surgery and aims to optimize patient outcomes and reduce the need for revision surgeries. Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is further developing the aprevo Technology Platform for use in cervical spine fusion surgeries, which is slated for launch in 2026.
Carlsmed publicly filed a registration statement with the SEC relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Carlsmed has applied to list its common stock on the Nasdaq Global Select Market under the ticker...
Carlsmed publicly filed a registration statement with the SEC relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Carlsmed has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol CARL.
BofA Securities, Goldman Sachs and Piper Sandler are acting as joint lead book-running managers and representatives of the underwriters for the proposed offering. Truist Securities and BTIG are acting as joint book-runners for the proposed offering.
The proposed offering will be made only by means of a prospectus.
The aprevo Technology Platform consists of artificial intelligence-enabled software solutions and interbody implants that are custom-designed for each patient’s pathology and vertebral bone topography, as well as single-use surgical instruments. The aprevo Technology Platform was designed to address the limitations of traditional spine fusion surgery and aims to optimize patient outcomes and reduce the need for revision surgeries. Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is further developing the aprevo Technology Platform for use in cervical spine fusion surgeries, which is slated for launch in 2026.
Copy to clipboard 
